Canaccord Adams Initiates Coverage on XOMA (XOMA) with a Buy; XOMA-052 Promising New Type 2 Diabetes Drug
Tweet Send to a Friend
Canaccord Adams initiates coverage on XOMA (Nasdaq: XOMA) with a Buy.
Canaccord analyst says, "While Type 2 diabetes represents a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "While Type 2 diabetes represents a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
